A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

ClinicalTrials.gov ID: NCT07532265

Public ClinicalTrials.gov record NCT07532265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Study identification

NCT ID: NCT07532265
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Kinaset Therapeutics Inc; Industry
Enrollment: 512 participants

Conditions and interventions

Conditions

Severe Asthma

Interventions

Frevecitinib Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2026
Primary completion: Nov 29, 2027
Completion: Nov 29, 2027
Last update posted: Jul 27, 2026

2026 – 2027

United States locations

U.S. sites: 14
U.S. states: 9
U.S. cities: 14

Facility	City	State	ZIP	Site status
Research site	Lancaster	California	93534	Recruiting
Research site	San Jose	California	95117	Recruiting
Research site	Brandon	Florida	33511	Not yet recruiting
Research site	Miami	Florida	33137	Recruiting
Research site	Tampa	Florida	33607	Recruiting
Research site	Chicago	Illinois	60612	Not yet recruiting
Research site	Kansas City	Missouri	66160	Not yet recruiting
Research site	Charlotte	North Carolina	28277	Recruiting
Research site	Pittsburgh	Pennsylvania	15213	Not yet recruiting
Research site	Rock Hill	South Carolina	29732	Recruiting
Research site	Dallas	Texas	75225	Recruiting
Research site	Houston	Texas	77099	Recruiting
Research site	San Antonio	Texas	78258	Recruiting
Research site	Williamsburg	Virginia	23188	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07532265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 27, 2026 · Synced Sep 13, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07532265 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →